Vitae Pharmaceuticals (VTAE) Reports In-Line Q2 EPS

Vitae Pharmaceuticals (NASDAQ: VTAE) reported Q2 EPS of ($0.45), in-line with the analyst estimate of ($0.45). Revenue for the quarter came in at $161.6 thousand versus the consensus estimate of $80 thousand.

For earnings history and earnings-related data on Vitae Pharmaceuticals (VTAE) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance
• LogicBio Therapeutics (LOGC) Misses Q2 EPS by 10c